Comprehensive Breakdown of Strong Leading Stocks on August 11

【Answer 1】 1. Sector: Industrial Gases 2. Driving Logic: Domestic substitution of industrial gases; breakthroughs in domestically produced electronic specialty gases; downstream demand from chemical and semiconductor industries 3. Moat: Gas production and hazardous chemicals operation licenses; regional customer barriers 4. Funding Landscape: Small- to mid-cap stock; attracts some growth-oriented institutional investors and theme-driven retail traders 5. Potential Catalysts: Ramp-up in volume of electronic specialty gas products; expansion of downstream semiconductor fabrication plants 6. Key Risks: Project commissioning progress falling short of expectations; intensifying competition in the industrial gas industry 14. 600721 Baihua Pharmaceutical 1. Sector: Pharmaceutical CRO + Traditional Chinese Medicine (TCM) 2. Driving Logic: TCM-themed investment; CRO service business; small-cap restructuring speculation attributes 3. Moat: CRO service team; TCM regulatory approvals; relatively weak competitive barriers 4. Funding Landscape: Purely speculative short-term trading target for retail traders; minimal institutional participation 5. Potential Catalysts: TCM-related policy support; realization of CRO orders 6. Key Risks: Small earnings base; low profitability stability in core operations 15. 600206 YG Advanced Materials 1. Sector: Semiconductor sputtering targets, rare-earth new materials 2. Driving Logic: Domestic substitution of semiconductor materials; rare-earth metal business; state-owned enterprise (SOE) scientific research background 3. Moat: SOE scientific research platform; technical accumulation in sputtering targets and rare-earth materials; certain materials lead domestically 4. Funding Landscape: Semiconductor new-materials sector; mixed institutional and retail trader participation; moves in tandem with the broader semiconductor sector 5. Potential Catalysts: Accelerated domestic semiconductor adoption; rising rare-earth prices 6. Key Risks: Cyclical volatility in the downstream semiconductor industry; mass-production progress of new materials lagging expectations 16. 600833 First Medical 1. Sector: Pharmaceutical retail 2. Driving Logic: Shanghai-based state-owned pharmaceutical retailer; TCM consumer theme; small-cap shell speculation 3. Moat: Physical pharmacy network across Shanghai; time-honored brand; no technological barriers 4. Funding Landscape: Short-term thematic trading by retail traders; negligible institutional holdings 5. Potential Catalysts: Shanghai state-owned asset reform; recovery in pharmaceutical consumption 6. Key Risks: Fierce competition in the retail sector; limited earnings growth potential 17. 600641 Xian Dao Jidian (XDJ) 1. Sector: Integrated power services, green electricity 2. Driving Logic: Green electricity operations; integrated energy services; SOE platform; transition toward new energy 3. Moat: Local energy platform resources; land and power station advantages 4. Funding Landscape: Public utility sector; partial institutional allocation; thematic capital rotation 5. Potential Catalysts: Implementation of new energy projects; supportive green electricity policies 6. Key Risks: Large project investments with long payback periods; electricity pricing policy changes 18. 002552 Baoding Technology 1. Sector: Heavy-equipment forgings, offshore wind & marine engineering 2. Driving Logic: Large-scale forgings for offshore wind and marine engineering; construction of offshore wind farms; SOE background 3. Moat: Manufacturing process qualifications for large forgings; production capacity for heavy-equipment machining 4. Funding Landscape: Small-cap wind-power theme; retail-trader dominated; follows broader wind-power sector movements 5. Potential Catalysts: Large-scale commencement of offshore wind projects; order growth 6. Key Risks: Lower-than-expected wind installation volumes; rising steel raw material prices 19. 002963 Haor Sai

In-Depth Investment Value Assessment of Harbin Pharmaceutical Group Co., Ltd. (600664) — October 12, 2026

【Answer 2】 Summary of Moat: Harbin Pharmaceutical Group’s moat lies primarily in brand recognition and distribution coverage— as one of China’s largest pharmaceutical enterprises, its core products hold notable market shares within their respective niche segments. Its pharmaceutical manufacturing segment boasts a gross margin of 57.24%, and market share for key products has increased by approximately 4%, yielding multiple 'golden products' generating annual revenues of RMB 500 million or RMB 100 million. Its pharmaceutical distribution network expanded by 100,000 new retail terminals year-on-year. The company continues enriching its product pipeline: 86 resumed products have successfully launched, and its sodium sulfate active pharmaceutical ingredient (API) application received approval in July 2026. However, GuruFocus assigns it a GF Score of 66/100, classifying the stock as 'significantly overvalued', with a GF Value of only RMB 3.51. A 42.50% YoY decline in net profit attributable to shareholders in 2025—and cumulative unremedied losses at the parent level exceeding RMB 2 billion—highlight deep-seated challenges to profitability and asset quality. On October 12, 2026, the company’s president was placed under investigation and placed in detention, triggering an immediate, full-limit downward price movement—a major corporate governance red flag. V. Financial Snapshot — Revenue and Profits Declined in 2025, Marked Improvement in H1 2026 1. Core Financial Metrics Indicator 2025 2026 Q1 2026 H1 2026 H1 YoY Assessment Operating Revenue RMB 15.964 billion (−1.31% YoY) RMB 4.179 billion RMB 8.296 billion +2.10% 🟡 Slight Growth Net Profit Attributable to Shareholders RMB 362 million (−42.50% YoY) ~RMB 210 million RMB 410 million +57.99% 🟢 Significant Improvement Net Profit Attributable to Shareholders (Excl. Non-recurring Gains/Losses) ~RMB 173 million (−52.09% YoY) Not disclosed per company announcement RMB 355 million +45.39% 🟢 Significant Improvement Gross Margin 25.98% (−2.26 ppts YoY) Not disclosed per company announcement Not disclosed per company announcement Not disclosed per company announcement 🟡 Under Pressure Pharmaceutical Manufacturing Gross Margin 57.24% (−1.68 ppts YoY) Not disclosed per company announcement Not disclosed per company announcement Not disclosed per company announcement 🟢 Relatively High Basic EPS (RMB) RMB 0.14 ~RMB 0.08 RMB 0.16 Not disclosed per company announcement 🟢 Improvement Weighted Average ROE 6.36% Not disclosed per company announcement Not disclosed per company announcement Not disclosed per company announcement 🟡 Needs Improvement Net Cash Flow from Operating Activities Not disclosed per company announcement Not disclosed per company announcement −RMB 462,600 Shifted from positive to negative 🔴 Deterioration Distributable Profits at Parent Level −RMB 2.053 billion Not disclosed per company announcement Not disclosed per company announcement Not disclosed per company announcement 🔴 Massive Unremedied Losses Forward P/E Ratio Not disclosed per company announcement Not disclosed per company announcement Not disclosed per company announcement 20.41x 🟢 Relatively Low Forward P/B Ratio Not disclosed per company announcement Not disclosed per company announcement Not disclosed per company announcement 2.74x 🟡 Reasonably High Total Market Capitalization — — RMB 16.748 billion — —

5 Stocks with Moat Rating Changes This Month

Oct 13, 2026

Morningstar updated economic moat ratings for five US stocks, downgrading Eastman Chemical and Celanese to 'no moat' due to acquisition issues, while upgrading Martin Marietta and Vulcan Materials to 'wide moat'.

Morningstar

2026-01-30

Eastman Chemical, Kolmar Korea Forge Partnership to Advance Biodegradable Personal Care Solutions

2026-04-06

Eastman Chemical Co (EMN) Shares Drop 3.04% on April 6

2026-04-06

Eastman Chemical Co. Stock Underperforms Monday Compared to Competitors

2026-04-08

Global Amines Market Growth Driven by Arkema, Eastman Chemical in North America and Europe Expansion

2026-04-08

Eastman to Post Q1 Results April 30, Hold Webcast May 1